Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

The researchers aimed to assess the effects of either human atrial natriuretic peptide or nicorandil on infarct size and cardiovascular outcome.

Why It Was Studied

Patients who have acute myocardial infarction remain at major risk of cardiovascular events.

Who Took Part

The abstract describes 1216 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

The researchers enrolled 1216 patients who had acute myocardial infarction and were undergoing reperfusion treatment in two prospective, single-blind trials at 65 hospitals in Japan.

Median follow-up was 2.7 (IQR 1.5-3.6) years for patients in the atrial natriuretic peptide trial and 2.5 (1.5-3.7) years for those in the nicorandil trial.

How the Study Was Run

The researchers set it up as a randomized, single-blind and placebo-controlled study.

The patients were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

Only one side, usually the patients, was kept unaware of whether ANP (Atrial Natriuretic Peptide) was given.

Some patients received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

Primary endpoints were infarct size (estimated from creatine kinase) and left ventricular ejection fraction (gauged by angiography of the left ventricle).

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Creatine Kinase, Japan, Myocardial Infarction, Nicorandil, Reperfusion Injury and Vasodilator Agents.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 1216 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Lancet (London, England)), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.